Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03029013
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03026881
- Locations
- 🇨🇳
The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- First Affiliated Hospital Bengbu Medical College
- Target Recruit Count
- 120
- Registration Number
- NCT03020979
- Locations
- 🇨🇳
Qiong Wu, Bengbu, Anhui, China
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03007446
- Locations
- 🇨🇳
the chinese PLA General Hospital, Beijing, China
Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02998242
Apatinib for Advanced Non-squamous Head and Neck Cancer
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2016-12-13
- Target Recruit Count
- 30
- Registration Number
- NCT02989259
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, Beijing, China
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2016-12-02
- Target Recruit Count
- 60
- Registration Number
- NCT02980809
Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Fan Yun, MD
- Target Recruit Count
- 40
- Registration Number
- NCT02945852
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2018-02-26
- Target Recruit Count
- 60
- Registration Number
- NCT02942329
- Locations
- 🇨🇳
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing, Beijing, China
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Shanghai Proton and Heavy Ion Center
- Target Recruit Count
- 50
- Registration Number
- NCT02942693
- Locations
- 🇨🇳
Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.